HCM — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00
- £2.34bn
- £1.70bn
- $838.00m
- 85
- 20
- 62
- 57
RCS - Hutchmed China Ltd - Clinical Data to be Presented at Congresses
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - U.S. FDA Approval of FRUZAQLA™ (fruquintinib)
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ESMO 2023
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - NDA Submission for Fruquintinib in Japan
AnnouncementREG - Hutchmed China Ltd - Director’s Share Dealing
AnnouncementRCS - Hutchmed China Ltd - Phase IIIb Savolitinib Results at WCLC 2023
AnnouncementRCS - Hutchmed China Ltd - Patient Enrollment Completed for Bridging Study
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - BTD in China for Savolitinib for Gastric Cancer
AnnouncementREG - Hutchmed China Ltd - Sovleplenib Phase 3 Study Meets Primary Endpoint
AnnouncementREG - Hutchmed China Ltd - Exercise of Share Options by a Director
AnnouncementREG - Hutchmed China Ltd - Interim Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Breakthrough Therapy Designation for Fruquintinib
AnnouncementREG - Hutchmed China Ltd - Changes to Board and Technical Committee
AnnouncementRCS - Hutchmed China Ltd - Phase 1 Study of HMPL-415 Initiated
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
Announcement